Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318

Figure 5

(a) Biodistribution (%ID/g) of [⁸⁹Zr]Zr-DFO-NC318 in 624-MEL+S15 xenografts at 3 d after receiving coinjections of [⁸⁹Zr]Zr-DFO-NC318 (~0.8 μg) + NC318 (0 (control), 20, 100, and 300 μg). Each bar represents the mean (-10 for each group). (b, c) [⁸⁹Zr]Zr-DFO-NC318 tissue (%ID/g) to blood (%ID/g) ratios (T : B; (b)) or tissue (%ID/g) to muscle (%ID/g) ratios (T : M; (c)) in 624-MEL+S15 xenografts 3 d after receiving coinjections of [⁸⁹Zr]Zr-DFO-NC318 (~0.8 μg) + NC318 (0 (control), 20, 100, and 300 μg). Each bar represents the mean (-10 for each group); ; ; (Student’s -test): indicates a significant difference between the T : B (b) or T : M (c) ratios of each NC318-dosed group compared to respective [⁸⁹Zr]Zr-DFO-NC318 controls (0 NC318 μg dose) in Siglec-15+ tissues (lymph nodes, spleen, tumor, and femur). (d, e) [⁸⁹Zr]Zr-DFO-NC318 tumor uptakes (%ID/g (d)) and T : M ratios (e) in 624-MEL+S15 (), LOX IMIV (), HCC-827 (), and 624-MEL wild-type (WT; ) xenografts after 3 d. Each bar represents the . ; ; (Student’s -test): indicates a significant difference between the %ID/g (d) or T : M (e) ratios between the indicated 2 tumor types.

(a)

(b)

(c)

(d)

(e)